Clonal Evaluation of Prostate Cancer by ERG/SPINK1 Status to Improve Prognosis Prediction
Abstract
Prostate cancer is usually multiclonal, meaning that most men with prostate cancer have multiple, genetically distinct cancers. Pathologists cannot assess clonality by routine microscopic evaluation, and hence multiclonality is not incorporated into routinely reported pathological parameters. Given the importance of routine pathological parameters in prostate cancer prognosis, the potential to refine these parameters through assessing multiclonality represents a major opportunity. Hence, in this proposal we utilized dual ERG/SPINK1 immunohistochemistry (IHC)as a readout of clonal, mutually exclusive molecular subtypesto assess the frequency of multiclonality in key clinical scenarios at biopsy and resection and its impact on prognostic parameters. Our published and unpublished findings confirm multiclonality in key diagnostic scenarios, including discontinuously involved cores, multiple involved cores at biopsy, and collision tumors at prostatectomy. Our results are thus highly impactful for the management of men with prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2017
- Accession Number
- AD1048745
Entities
People
- Scott A. Tomlins
Organizations
- Board of Regents of the University of Michigan